COLD-ADAPTED EQUINE INFLUENZA VIRUSES

Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine inlfuenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions. Such methods include using a therapeutic composition as a vaccine to generate a protective immune response in an animal prior to exposure to a virulent virus, and using a therapeutic composition as a treatment for an animal that has been recently infected with a virulent virus, or is likely to be subsequently exposed to virulent viruses in a few days whereby the therapeutic composition interferes with the growth of the virulent virus, even in the absence of immunity. The present invention also provides methods to produce cold-adapted equine influenza viruses, and reassortant influenza A viruses having at least one genome segment of an equine influenza virus generated by cold-adaptation.

Description: COLD-ADAPTED EQUINE INFLUENZA VIRUSES CROSS-REFERENCE TO RELATED APPLICATION This application claims priority to U.S. Patent Application Serial No. 09/506,286, filed February 16, 2000, entitled COLD- ADAPTED EQUINE INFLUENZA VIRUSES, which is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION The present invention relates to nucleic acids and proteins of experimentally- generated cold-adapted equine influenza viruses, and particularly to cold-adapted equine influenza viruses having additional phenotypes, such as attenuation, dominant interference, or temperature sensitivity. The invention also includes reassortant influenza A " viruses which contain at least one genome segment from such an equine influenza virus, such that the reassortant virus includes certain phenotypes of the donor equine influenza virus. The invention further includes genetically-engineered equine influenza viruses, produced through reverse genetics, which comprise certain identifying phenotypes of a cold-adapted equine influenza virus of the present invention. The present invention also relates to the use of these viruses in therapeutic compositions to protect animals from diseases caused by influenza viruses. BACKGROUND OF THE INVENTION Equine influenza virus has been recognized as a major respiratory pathogen in horses since about 1956. Disease symptoms caused by equine influenza virus can be severe, and are often followed by secondary bacterial infections. Two subtypes of equine influenza virus are recognized, namely subtype- 1, the prototype being A/Equine/Prague/1/56 (H7N7), and subtype-2, the prototype being A/Equine/Miami/ 1/63 (H3N8). Presently, the predominant virus subtype is subtype-2, which has further diverged among Eurasian and North American isolates in recent years. The currently licensed vaccine for equine influenza is an inactivated (killed) virus vaccine. This vaccine provides minimal, if any, protection for horses, and can produce undesirable side effects, for example, inflammatory reactions at the site of injection. See, e.g., Mumford, 1987, Equine Infectious Disease IV, 207-217, and Mumford, et al., 1993, Vaccine 11, 1172- 1174. Furthermore, current modalities cannot be used in young foals, because they cannot overcome maternal immunity, and can induce tolerance in a younger animal. Based on the severity of disease, there remains a need for safe, effective therapeutic compositions to protect horses against equine influenza disease. Production of therapeutic compositions comprising cold-adapted human influenza viruses is described, for example, in Maassab, et al., 1960, Nature 7,612-614, and Maassab, et al, 1969, J. Immunol. 102, 728-732. Furthermore, these researchers noted that cold-adapted human influenza viruses, i.e., viruses that have been adapted to grow at lower than normal temperatures, tend to have a phenotype wherein the virus is temperature sensitive; that is, the virus does not grow well at certain higher, non- permissive temperatures at which the wild-type virus will grow and replicate. Various cold-adapted human influenza A viruses, produced by reassortment with existing cold- adapted human influenza A viruses, have been shown to elicit good immune responses in vaccinated individuals, and certain live attenuated cold-adapted reassortant human influenza A viruses have proven to protect humans against challenge with wild-type virus. See, e.g., Clements, et al., 1986, J. Clin. Microbiol. 23, 73-76. In U.S. Patent No. 5,149,531, by Youngner, et al., issued September 22, 1992, the inventors of the present invention further demonstrated that certain reassortant cold-adapted human influenza A viruses also possess a dominant interference phenotype, i.e., they inhibit the growth of their corresponding parental wild-type strain, as well as heterologous influenza A viruses. U.S. Patent No. 4,683,137, by Coggins et al., issued July 28, 1987, and U.S. Patent No. 4,693,893, by Campbell, issued September 15, 1987, disclose attenuated therapeutic compositions produced by reassortment of wild-type equine influenza viruses with attenuated, cold-adapted human influenza A viruses. Although these therapeutic compositions appear to be generally safe and effective in horses, they pose a significant danger of introducing into the environment a virus containing both human and equine influenza genes. SUMMARY OF THE INVENTION The present invention provides nucleic acids and proteins of experimentally- generated cold-adapted equine influenza viruses, and reassortant influenza A viruses. Examples of cold-adapted equine influenza viruses of the present invention include EIV-P821, identified by accession No. ATCC VR-2625; EIV-P824, identified by accession No. ATCC VR-2624; EIV-MSV+5, identified by accession No. ATCC VR-627; and progeny of such viruses. Cold-adapted equine influenza viruses of the invention, and their methods of making, are disclosed in related U.S. Patent No. 6,177,082, by Dowling et al, issued January 23, 2001; and WO 00/09702, by Dowling et al., published February 24, 2000, both of which are incorporated herein by reference in their entirety. The present invention also describes nucleic acid molecules encoding wild-type and cold-adapted equine influenza proteins PB2, NS, PB1, PA and NA. One embodiment of the present invention is an isolated equine nucleic acid molecule having a nucleic acid sequence selected from a group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ LD NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO: 100 and SEQ ID NO: 102 and a nucleic acid molecule comprising a nucleic acid sequence which is fully complementary to any of such nucleic acid sequences. Another embodiment of the present invention is an isolated equine nucleic acid molecule that encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9, SEQ ED NO: 14, SEQ ID NO:22, SEQ ID NO.25, SEQ ID NO:28, SEQ ID NO.33, SEQ ID NO.37, SEQ ID NO.40, SEQ ED NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:72, SEQ ED NO:77, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:96, SEQ ED NO:99, SEQ ID NO: 101 and SEQ ID NO: 103. Another embodiment is an isolated equine influenza protein that comprises an amino acid sequence selected from a group consisting of SEQ ED NO: 6, SEQ ED NO: 9, SEQ ID NO: 14, SEQ ID NO:22, SEQ DD NO:25, SEQ ED NO:28, SEQ DD NO:33, SEQ DD NO.37, SEQ DD NO:40, SEQ DD NO:43, SEQ ED NO:46, SEQ DD NO:49, SEQ DD NO:54, SEQ DD NO:62, SEQ DD NO:64, SEQ DD NO:67, SEQ DD NO:69, SEQ DD NO:72, SEQ DD NO:77, SEQ DD NO:85, SEQ ED NO:88, SEQ DD NO:96, SEQ ED NO:99, SEQ DD NO:101 and SEQ ED NO:103. Also included in the present invention is a virus that include any of these nucleic acid molecules or proteins. In one embodiment, such a virus is equine influenza virus or a reassortant virus. DETAILED DESCRIPTION OF THE INVENTION The present invention provides nucleic acids and proteins of experimentally- generated cold-adapted equine influenza viruses comprising certain defined phenotypes, which are disclosed herein. It is to be noted that the term "a" or "an" entity, refers to one or more of that entity; for example, "a cold-adapted equine influenza virus" can include one or more cold-adapted equine influenza viruses. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising," "including," and "having" can be used interchangeably. Furthermore, an item "selected from the group consisting of refers to one or more of the items in that group, including combinations thereof. A cold-adapted equine influenza virus of the present invention is a virus that has been generated in the laboratory, and as such, is not a virus as occurs in nature. Since the present invention also includes those viruses having the identifying phenotypes of such a cold-adapted equine influenza virus, an equine influenza virus isolated from a mixture of naturally-occurring viruses, i.e., removed from its natural milieu, but having the claimed phenotypes, is included in the present invention. A cold-adapted equine influenza virus of the present invention does not require any specific level of purity. For example, a cold- adapted equine influenza virus grown in embryonated chicken eggs may be in a mixture with the allantoic fluid (AF), and a cold-adapted equine influenza virus grown in tissue culture cells may be in a mixture with disrupted cells and tissue culture medium. As used herein, an "equine influenza virus" is an influenza virus that infects and grows in equids, e.g., horses or ponies. As used herein, "growth" of a virus denotes the ability of the virus to reproduce or "replicate" itself in a permissive host cell. As such, the terms, "growth of a virus" and "replication of a virus" are used interchangeably herein. Growth or replication of a virus in a particular host cell can be demonstrated and measured by standard methods well-known to those skilled in the art of virology. For example, samples containing infectious virus, e.g., as contained in nasopharyngeal secretions from an infected horse, are tested for their ability to cause cytopathic effect (CPE), e.g., virus plaques, in tissue culture cells. Infectious virus may also be detected by inoculation of a sample into the allantoic cavity of embryonated chicken eggs, and then testing the AF of eggs thus inoculated for its ability to agglutinate red blood cells, i.e., cause hemagglutination, due to the presence of the influenza virus hemagglutinin (HA) protein in the AF. Cold-adapted equine influenza viruses of the present invention are characterized primarily by one or more of the following identifying phenotypes: cold- adaptation, temperature sensitivity, dominant interference, and/or attenuation. As used herein, the phrase "an equine influenza virus comprises the identifying phenotype(s) of cold-adaptation, temperature sensitivity, dominant interference, and/or attenuation" refers to a virus having such a phenotype(s). Examples of such viruses include, but are not limited to, EIV-P821, identified by accession No. ATCC VR-2625, EIV-P824, identified by accession No. ATCC VR-2624, and EIV-MSV+5, identified by accession No. ATCC VR-2627, as well as EIV-MSVO, EIV, MSV+1, EIV-MSV+2, EIV-MSV+3, and EIN- MSN+4. Pursuant to 37 CFR § 1.802 (a-c), cold-adapted equine influenza viruses, designated herein as EIN-P821, an EIN-P824 were deposited with the American Type Culture Collection (ATCC, 10801 University Boulevard, Manassas, NA 20110-2209) under the Budapest Treaty as ATCC Accession Νos. ATCC NR-2625, and ATCC NR- 2624, respectively, on July 11, 1998. Cold-adapted equine influenza virus EIN-MSN+5 was deposited with the ATCC as ATCC Accession No. ATCC VR-2627on August 3, 1998. Pursuant to 37 CFR§ 1.806, the deposits are made for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposit was received by the depository. Pursuant to 37 CFR § 1.808 (a)(2), all restrictions imposed by the depositor on the availability to the public will be irrevocably removed upon the granting of the patent. The present invention includes nucleic acid molecules isolated from equine influenza virus wild type strain A/equine/Kentucky/1/91 (H3N8), and cold-adapted equine influenza virus EIV-P821. In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation) and can include DNA, RNA, or derivatives of either DNA or RNA. As such, "isolated" does not reflect the extent to which the nucleic acid molecule has been purified. The present invention includes nucleic acid molecules encoding wild-type and cold-adapted equine influenza virus proteins. Nucleic acid molecules of the present invention can be prepared by methods known to one skilled in the art. Proteins of the present invention can be prepared by methods known to one skilled in the art, i.e., recombinant DNA technology. Preferred nucleic acid molecules have coding strands comprising nucleic acid sequences SEQ DD NO: 5, SEQ DD NO: 7, SEQ DD NO: 8, SEQ DD O:10, SEQ ID NO: 13, SEQ ID NO: 19, SEQ DD NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ED NO:24, SEQ DD NO:26, SEQ DD NO:27, SEQ ID NO:29, SEQ DD NO:32, SEQ DD NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ED NO:41, SEQ ED NO:42, SEQ ED NO:44, SEQ DD NO:45, SEQ ED NO:47, SEQ ID NO:48, SEQ ED NO:50, SEQ ED NO:51, SEQ DD NO:53, SEQ ED NO:60, SEQ DD NO:61, SEQ DD NO:63, SEQ DD NO:65, SEQ DD NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ DD NO:71, SEQ DD NO:73, SEQ DD NO:76, SEQ DD NO:82, SEQ ED NO:83, SEQ DD NO:84, SEQ DD NO:86, SEQ ID NO:87, SEQ DD NO:89, SEQ DD NO:94, SEQ DD NO:95, SEQ DD NO:97, SEQ DD NO:98, SEQ D NO: 100 and SEQ DD NO: 102 and/or a complement thereof. Complements are defined as two single strands of nucleic acid in which the nucleotide sequence is such that they will hybridize as a result of base pairing throughout their full length. Given a nucleotide sequence, one of ordinary skill in the art can deduce the complement. Preferred nucleic acid molecules encoding equine influenza PB2 proteins are nei wt PB2 23 ι, nei wt PB2 2277 , nei ca ιPB2 234 ι, and/or nei ca ιPB2 2277 , the coding strands of which are represented by SEQ DD NO:24, SEQ DD NO:26, SEQ DD NO:27, and/or SEQ ED NO:29. Preferred nucleic acid molecules encoding equine influenza NS proteins are neiwtiNSggi, neiwtiNSego, neiwβNSgss, ne NS^s, neiwt NS 293 , nei ca ιNS 8 88, and/or nei ca iNS 69 o, the coding strands of which are represented by SEQ DD NO 32, SEQ DD NO 34, SEQ DD NO 35, SEQ DD NO 36, SEQ ID NO 38, SEQ DD NO 39 and/or SEQ ID NO 41 Preferred nucleic acid molecules encoding equine influenza PB1-N proteins are neiwtιPBl-Nι 229 , neiwtιPBl-Nπ 9 , neiwt 2 PBl-N 673 , neiwt 2 PBl-N 63 6, nei ca ιPBl-Nι 225 , nei C aiPBl-Nii 85 , nei ca2 PBl-Nι 22 ι, and/or nei ca2 PBl-Nn85, the coding strands of which are represented by SEQ DD NO 42, SEQ ID NO 44, SEQ DD NO 45, SEQ DD NO 47, SEQ DD NO 48, SEQ DD NO 50, and/or SEQ ID NO 51 Preferred nucleic acid molecules encoding equine influenza PB1-C proteins are neiwtιPBl-C 1234 , neiwtiPBl-Ci , neiwβPBl-Cmn, nei_ a ιPBl-C 1241 , nei oa ιPBl-Cπ88, and/or nei ca PBl-C 12 ι, the coding strands of which are represented by SEQ DD NO 53, SEQ DD NO 60, SEQ DD NO 61, SEQ ID NO 63, SEQ ID NO 65, SEQ ID NO 66, and/or SEQ ID NO 94 Preferred nucleic acid molecules encoding equine influenza PB1 proteins are neiwtPBl 2341 , neiwtPBl 2271 , nei ca ιPBl 234 ι, nei ca ιPBl 2271 , the coding strands of which are represented by SEQ ID NO 68, SEQ DD NO 70, SEQ DD NO 71, and/or SEQ DD NO 73 Preferred nucleic acid molecules encoding equine influenza PA-C proteins are nei cal PA-Cι 233 , and nei 0 aiPA-Cn 7 o, the coding strands of which are represented by SEQ DD NO 76, SEQ DD NO 82, SEQ ED NO 83, SEQ DD NO 84, and/or SEQ DD NO 86 Preferred nucleic acid molecules encoding equine influenza PA-N proteins are neiwtPA-Nι 216 , neiwtPA-Nn 93 , nei ca PA-Nι ι 7 , and nei ca PA-Nπ9 3 , the coding strands of which are represented by SEQ DD NO 94, SEQ DD NO 95, SEQ DD NO 97 and SEQ ID NO 98 Preferred nucleic acid molecules encoding equine influenza PA proteins are neiwtPA 2 ι 4 s and nei oa PA 2 ι 4 8, the coding strands of which are represented by SEQ ED NO 100 and SEQ DD NO 102 Preferred nucleic acid molecules encoding equine influenza NA proteins are nei ca NAι 47 s and nei ca NA 1 ι 0 , the coding strands of which are represented by SEQ ED NO:87 and SEQ DD NO:89. The present invention includes proteins comprising SEQ DD NO: 6, SEQ ED NO: 9, SEQ DD NO: 14, SEQ ED NO:22, SEQ ED NO:25, SEQ DD NO:28, SEQ ID NO:33, SEQ DD NO:37, SEQ DD NO:40, SEQ DD NO:43, SEQ DD NO:46, SEQ DD NO:49, SEQ DD NO:54, SEQ ED NO:62, SEQ DD NO:64, SEQ DD NO:67, SEQ ED NO:69, SEQ DD NO:72, SEQ DD NO:77, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:96, SEQ ID NO:99, SEQ DD NO: 101 and SEQ DD NO: 103 as well as nucleic acid molecules encoding such proteins. Preferred equine influenza PB2-N proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei wt PB2-N 1 41 , neiwtPB2-Nι 214 , nei 0 aiPB2-Ni 24 i, nei ca ιPB2-N 1 ι 4 nei ca2 , and/or PB2-N 1 ι 4 . Preferred equine influenza PB2-N proteins are P wt PB2-N 404 , P_aiPB2-N 40 , and/or P ca2 PB2-N 40 . In one embodiment, a preferred equine influenza PB2-N protein of the present invention is encoded by SEQ DD NO:5, SEQ DD NO:7, SEQ DD NO:8, and/or SEQ DD NO: 10, and, as such, has an amino acid sequence that includes SEQ DD NO: 6 and/or SEQ DD NO: 9. Preferred equine influenza PB2-C proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei wt ιPB2-C 1233 , neiwt PB2-Cι 2 , neiwtPB2-C 1194 , nei oa ιPB2-C 1232 , and/or nei ca ιPB2-Cιi9 4 . In one embodiment, a preferred equine influenza PB2-C protein of the present invention is encoded by SEQ DD NO: 13, SEQ DD NO:20, SEQ DD NO: 19, SEQ ED NO:21, and/or SEQ DD NO:23, and, as such, has an amino acid sequence that includes SEQ DD NO: 14 and/or SEQ ED NO: 22. Preferred equine influenza PB2 proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei wt PB2 2341 , nei wt PB2 2277 , nei cal PB2 2341 , and or nei ca ιPB2 2277 . In one embodiment, a preferred equine influenza PB2 protein of the present invention is encoded by SEQ DD NO:24, SEQ DD NO:26, SEQ DD NO:27, and/or SEQ DD NO.29, and, as such, has an amino acid sequence that includes SEQ DD NO:25 and/or SEQ DD NO:28. Preferred equine influenza NS proteins of the present invention include proteins encoded by a nucleic acid molecule comprising neiwtiNSsgi, neiwtιNS6 o, neiwβ Sgss, neiwt NS 46 8, neiwt 4 NS 293 , nei ca ιNS 88 8, and/or nei ca ιNS 6 9o. Preferred equine influenza NS proteins are PeiwtNS 23 o, Peiwt 4 NS 97 , and/or Pei ca ιNS 23 o. In one embodiment, a preferred equine influenza NS protein of the present invention is encoded by SEQ DD NO:32, SEQ DD NO:34, SEQ DD NO:35, SEQ DD NO:36, SEQ DD NO:38, SEQ DD NO:39 and/or SEQ DD NO:41, and, as such, has an amino acid sequence that includes SEQ DD NO:33, SEQ ED NO:37 and/or SEQ DD NO:40. Preferred equine influenza PB1-N proteins of the present invention include proteins encoded by a nucleic acid molecule comprising neiwtιPBl-Nι 2 9, nei wt ιPBl-Nπ 94 , nei wt2 PBl-N6 3 , neiwt 2 PBl-N 63 6, nei cal PB21-N 1225 , nei cal PBl-Nn85, and/or nei ca2 PBl-N 1221 . Preferred equine influenza PB1-N proteins are Pei w tιPBl-N 39 8, Pwt 2 PBl-N 12 , and/or P cal PBl-N 395 . In one embodiment, a preferred equine influenza PB1-N protein of the present invention is encoded by SEQ DD NO:42, SEQ ED NO:44, SEQ DD NO:45, SEQ DD NO:47, SEQ DD NO:48, SEQ DD NO:50, and/or SEQ ED NO:51, and, as such, has an amino acid sequence that includes SEQ DD NO:43, SEQ ID NO:46 and/or SEQ ID NO:49. Preferred equine influenza PB1-C proteins of the present invention include proteins encoded by a nucleic acid molecule comprising neiwtιPBl-C 1 34 , neiwuPBl-Cπss, neiwt 2 PBl-Cι 240 , nei ca ιPBl-Cι 241 , nei cal PBl-Cιι 8 8, and/or nei ca2 PBl-C 124i . Preferred equine influenza PB1-C proteins are PeiwtιPBl-C 3 96, Pei ca ιPBl-C 96 , and/or Pei ca2 PBl-C 3 6. In one embodiment, a preferred equine influenza PB1-C protein of the present invention is encoded by SEQ ED NO:53, SEQ DD NO:60, SEQ DD NO:61, SEQ DD NO:63, SEQ ED NO.65, and/or SEQ ED NO:66, and, as such, has an amino acid sequence that includes SEQ ED NO:54, SEQ ED NO:62, SEQ ED NO:64, and/or SEQ ED NO:67. Preferred equine influenza PBl proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei wt PBl 2 4 ι, neiwtPBl 227 ι, nei ca ιPBl 234 ι, nei ca ιPBl 2271 . Preferred equine influenza PB 1 proteins are PeiwtPBl 757 , and/or Pei oa ιPBl 757 . In one embodiment, a preferred equine influenza PBl protein of the present invention is encoded by SEQ ED NO:68, SEQ ED NO:70, SEQ ED NO:71, and/or SEQ ED NO:73, and, as such, has an amino acid sequence that includes SEQ ED NO:69 and/or SEQ ED NO:72. Preferred equine influenza PA-C proteins of the present invention include proteins encoded by a nucleic acid molecule comprising neiwtiPA-Cπei, ne PA- C J223 , nei ca ιPA-Cι 233 , and/or nei cal PA-C 1170 . Preferred equine influenza PA-C proteins are PeiwtιPA-C 3 88, and/or Pei ca ιPA-C 39 o. In one embodiment, a preferred equine influenza PA-C protein of the present invention is encoded by SEQ ED NO: 76, SEQ ED NO:82, SEQ ED NO:83, SEQ ED NO:84, and/or SEQ DD NO:86, and, as such, has an amino acid sequence that includes SEQ ED NO: 77 and/or SEQ ED NO: 85. Preferred equine influenza PA-N proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei w tPA-Nmg, nei ca PA- Nι 2 π and nei ca PA-Nπ9 3 . Preferred equine influenza PA-N proteins are PeiwtPA-N 3 9 7 and/or Pei ca PA-N 397 . In one embodiment, a preferred equine influenza PA-N protein of the present invention is encoded by SEQ ED NO:94, SEQ DD NO:95, SEQ DD NO:97, and/or SEQ ED NO: 98, and, as such, has an amino acid sequence that includes SEQ DD NO:96 and/or SEQ ED NO:99. Preferred equine influenza PA proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei w tPA 214 8 and nei ca PA 2 ι 8. Preferred equine influenza PA proteins are PeiwtPA 7 i6 and/or Pei ca PA 71 6. In one embodiment, a preferred equine influenza PA protein of the present invention is encoded by SEQ ED NO: 100 and/or SEQ ED NO: 102, and, as such, has an amino acid sequence that includes SEQ ED NO:101 and/or SEQ ED NO:103. Preferred equine influenza NA proteins of the present invention include proteins encoded by a nucleic acid molecule comprising nei ca NA 147 s and nei ca NAi 41 n. A preferred equine influenza NA protein is Pei ca NA 470 . In one embodiment, a preferred equine influenza NA protein of the present invention is encoded by SEQ ED NO: 87 and/or SEQ ED NO:89, and, as such, has an amino acid sequence that includes SEQ DD NO.88. The present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PB2-N protein having an amino acid sequence comprising SEQ ED NO.9. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PB2- C protein having an amino acid sequence comprising SEQ DD NO: 22. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold- adapted equine influenza virus encoding a PB2 protein having an amino acid sequence comprising SEQ DD NO:28. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a NS protein having an amino acid sequence comprising SEQ ED NO: 40. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PB1-N protein having an amino acid sequence comprising SEQ ED NO:49. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PA-C protein having an amino acid sequence comprising SEQ ID NO: 85. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PB1-C protein having an amino acid sequence comprising SEQ ID NO: 64 and/or SEQ DD NO: 67. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PBl protein having an amino acid sequence comprising SEQ ED NO: 72. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PA-N protein having an amino acid sequence comprising SEQ ED NO: 99. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a PA protein having an amino acid sequence comprising SEQ ID NO: 103. Another embodiment of the present invention includes a nucleic acid molecule comprising a cold-adapted equine influenza virus encoding a NA protein having an amino acid sequence comprising SEQ ED NO:88. It should be noted that since nucleic acid sequencing technology is not entirely error-free, the nucleic acid sequences and amino acid sequences presented herein represent, respectively, apparent nucleic acid sequences of nucleic acid molecules of the present invention and apparent amino acid sequences of PB2-N, PB2-C, PB2, NS, PB1-N, PB1-C, PBl, PA-C, PA-N, PA, and NA proteins of the present invention. Another embodiment of the present invention is an antibody that selectively binds to an wild-type virus PB2-N, PB2-C, PB2, NS, PB1-N, PB1-C, PBl, PA-C, PA-N, PA and NA protein of the present invention. Another embodiment of the present invention is an antibody that selectively binds to a cold-adapted virus PB2-N, PB2-C, PB2, NS, PBl- N, PB1-C, PBl, PA-C, PA-N, PA and NA protein of the present invention. Preferred antibodies selectively bind to SEQ ED NO:6, SEQ DD NO:9, SEQ DD NO: 14, SEQ ED NO:22, SEQ ED NO:25, SEQ ED NO:28, SEQ ED NO:33, SEQ ED NO:37, SEQ ED NO:40, SEQ ED NO:43, SEQ ED NO:46, SEQ ED NO:49, SEQ ED NO:54, SEQ ED NO.62, SEQ ED NO:64, SEQ ED NO:67, SEQ ED NO:69, SEQ DD NO:72, SEQ DD NO:77, SEQ ED NO:85, SEQ ED NO:88, SEQ ED NO:96, SEQ ED NO:99, SEQ ED NO:101 and SEQ ED NO:103. The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention. Example 1 This example describes the cloning and sequencing of equine influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid molecules corresponding to the N- terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic ' acid molecules encoding wild type or cold-adapted equine influenza virus PB2-N proteins were produced as follows. A PCR product containing a N-terminal portion of the equine PB2 gene was produced by PCR amplification from equine influenza virus DNA, and primers w570 and w571, designated SEQ ID NO:36 and SEQ ED NO:37, respectively. A nucleic acid molecule of 1241 nucleotides encoding a wild type PB2-N protein, denoted nei w tPB2-N 124 ι, with a coding strand having a nucleic acid sequence designated SEQ ED NO: 13 was produced by further PCR amplification using the above described PCR product as a template and cloned into pCR 2.1 ® TA cloning vector, available from Invitrogen, Carlsbad, CA, using standard procedures recommended by the manufacturer. The primers used were the T7 primer, designated by SEQ ED NO:29 and the REV primer, designated by SEQ ED NO:28. Plasmid DNA was purified using a mini-prep method available from Qiagen, Valencia, CA. PCR products were prepared for sequencing using a PRISM™ Dye Terminator Cycle Sequencing Ready Reaction kit, a PRISM™ dRhodamine Terminator Cycle Sequencing Ready Reaction kit, or a PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction kit, all available from PE Applied Biosystems, Foster City, CA, following the manufacturer's protocol. Specific PCR conditions used with the kit were a rapid ramp to 95 °C, hold for 10 seconds followed by a rapid ramp to 50°C with a 5 second hold then a rapid ramp to 60°C with a 4 minute hold, repeating for 25 cycles. T7 and REV primers were used in one reaction. PCR products were purified by ethanol/magnesium chloride precipitation. Automated sequencing of DNA samples was performed using an ABI PRISM™ Model 377 with XL upgrade DNA Sequencer, available from PE Applied Biosystems. Translation of SEQ ED NO: 13 indicates that nucleic acid molecule nei wt PB2-N 124 ι encodes a N-terminal portion of influenza PB2 protein of about 404 amino acids, referred to herein as P w tPB2-N 4 o 4 , having amino acid sequence SEQ ED NO: 14, assuming an open reading frame in which the initiation codon spans from nucleotide 28 through nucleotide 30 of SEQ ED NO: 13, and the last codon spans from nucleotide 1237 through nucleotide 1239. The region encoding PwtPB2-N 4 o 4 , designated nei w tPB2-Nι 214 , and having a coding strand comprising nucleotides 28 to 1239 of SEQ ED NO: 13 is represented by SEQ ED NO: 15. B. A nucleic acid molecule of 1239 nucleotides encoding a N-terminal portion of influenza PB2 cold-adapted equine influenza virus PB2-N protein, denoted nei ca ιPB2- N12-U, with a coding strand having a sequence designated SEQ ED NO: 16 was produced, and sequenced as described in part A. Translation of SEQ ED NO: 16 indicates that nucleic acid molecule nei ca ιPB2-Nι ι encodes a -terminal portion of equine influenza PB-2 protein of about 404 amino acids, referred to herein as P ca ιPB2-N 04 , having amino acid sequence SEQ ED NO: 17, assuming an open reading frame in which the initiation codon spans from nucleotide 28 through nucleotide 30 of SEQ ED NO: 16, and the last codon spans from nucleotide 1237 through nucleotide 1239. The region encoding P ca ιPB2-N 404 , designated nei ca ιPB2-N 12 ι 4 , and having a coding strand comprising nucleotides 28 to 1239 of SEQ DD NO: 16, is represented by SEQ ED NO: 18. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza PB2-N protein in the same manner resulted in molecules nei oa2 PB2- Ni 24 i, identical to nei cal PB2-Nι 2 ι, and nei oa2 PB2-Nι 214 , identical to nei 0a ιPB2-N 121 . C. Comparison of the nucleic acid sequences of the coding strands of nei w tPB2- N1241 (SEQ ED NO: 13) and nei ca ιPB2-Nι 241 (SEQ ED NO: 16) by DNA alignment reveals the following difference: a T to C base shift at base 370. Comparison of the amino acid sequences of proteins P wt PB2-N 04 (SEQ ED NO: 14) and P ca ιPB2-N 404 (SEQ DD NO: 17) reveals the following difference: a Y to H shift at amino acid 124 relating to the a T to C shift at base 370 in the DNA sequence. Example 2 This example describes the cloning and sequencing of equine influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid molecules corresponding to the C- terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PB2-C proteins were produced as follows. A PCR product containing the C- terminal portion of the equine PB2 gene was produced by PCR amplification using from equine influenza virus DNA and primers w572 and w573, designated SEQ ED NO:38 and SEQ ID NO: 39, respectively. A nucleic acid molecule of 1233 nucleotides encoding a wild type PB2-C protein, denoted nei w tPB2-C 1 33 , with a coding strand having a nucleic acid sequence designated SEQ ED NO: 19 was produced by further PCR amplification using the above-described PCR product as a template and cloned as described in Example IB. Plasmid DNA was purified and sequenced as in Example 1 A, except that different primers were used in the sequencing kits. T7 and REV were used in one instance; efPB2-al, designated SEQ ED NO:40 and efPB2-sl, designated SEQ ID NO:41 were used in another instance, and efPB2-a2, designated SEQ ED NO: 42 and efPB2-s2, designated SEQ ED NO:43 were used in another instance. Translation of SEQ ED NO: 19 indicates that nucleic acid molecule neiwtιPB2-C 1233 encodes a C-terminal portion of influenza PB2 protein of about 398 amino acids, referred to herein as P w tPB2-C 398 , having amino acid sequence SEQ ED NO: 20, assuming an open reading frame having a first codon spans from nucleotide 3 through nucleotide 5 and a termination codon which spans from nucleotide 1197 through nucleotide 1199 of SEQ ED NO: 19. Because SEQ ED NO: 19 is only a partial gene sequence, it does not contain an initiation codon. The region encoding P wt PB2-C 39 s, designated nei wt PB2-Ci 194 , and having a coding strand comprising nucleotides 3 to 1196 of SEQ DD NO: 19 is represented by SEQ DD NO:21. PCR amplification of a second nucleic acid molecule encoding a wild type equine influenza PB2-N protein in the same manner resulted in a nucleic acid molecule of 1232 nucleotides denoted neiwβPB2-Nι 23 , with a coding strand with a sequence designated SEQ ED NO:22. nei wt2 PB2-N 1232 is identical to nei wtl PB2-C 1233 , expect that nei wt2 PB2- Nι 232 lacks one nucleotide on the 5'-end. Translation of SEQ ID NO:22 indicates that nucleic acid molecule nei wt ιPB2-Cι 233 also encodes PWIPB2-CS98 (SEQ DD NO:20), assuming an open reading frame having a first codon which spans from nucleotide 2 through nucleotide 4 and a termination codon spans from nucleotide 1196 through nucleotide 1198 of SEQ DD NO:22. Because SEQ DD NO:22 is only a partial gene sequence, it does not contain an initiation codon. The nucleic acid molecule having a coding strand comprising nucleotides 2 to 1195 of SEQ ID NO: 22, denoted nei w t 2 PB2- C U 94, is identical to SEQ ED NO:21. B. A nucleic acid molecule of 1232 nucleotides encoding a C-terminal portion of influenza PB2 cold-adapted equine influenza virus protein, denoted nei oal PB2-Cι 232 , and having a coding strand having a sequence designated SEQ ED NO:23 was produced as described in part A, except that the pCR ® -Blunt cloning vector was used. Translation of SEQ ED NO:23 indicates that nucleic acid molecule nei ca ιPB2-Cι 232 encodes a C-terminal portion of equine influenza PB-2 protein of about 398 amino acids, referred to herein as P ca ιPB2-C 3 98, having amino acid sequence SEQ ED NO:24, assuming, an open reading frame having a first codon which spans from nucleotide 2 through nucleotide 4 and a termination codon spans from nucleotide 1196 through nucleotide 1198 of SEQ ED NO:23. Because SEQ DD NO:23 is only a partial gene sequence, it does not contain an initiation codon. The region encoding P ca ιPB2-C 3 s, designated nei cal PB2- Cl 194, and having a coding strand comprising nucleotides 2 to 1195 of SEQ DD NO:23, is represented by SEQ ED NO:25. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza PB2-C protein in the same manner resulted in molecules nei ca2 PB2-Cι 231 , containing one less nucleotide at the 3 'end than nei cal PB2-N 12 1 ; and nei ca2 PB2-N 12 ι 4 , identical to nei ca ιPB2-N 12 ι 4 . C. Comparison of the nucleic acid sequences of the coding strands of nei wtl PB2- Cι 233 (SEQ ED NO: 19) and nei ca jPB2-C 1232 (SEQ ED NO:23) by DNA alignment reveals the following differences: . an A to C base shift at base 153 of SEQ ED NO: 19, and a G to A base shift at base 929 of SEQ ED NO: 19. Comparison of the amino acid sequences of proteins P wt PB2-C 398 (SEQ ED NO:20) and P ca1 PB2- 398 (SEQ ED NO:24) reveals the following difference: a K to Q shift at amino acid 51 when relating to the an A to C base shift at base 153 in the DNA sequences. There is no amino acid shift resulting from the G to A base shift at base 929. Example 3 This example describes the cloning and sequencing of equine influenza PB2 protein (RNA-directed RNA polymerase) nucleic acid molecules for wild type or cold- adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PB2 proteins were produced as follows. The wild type or cold-adapted equine influenza genes were cloned in two fragments, the N-terminal portion was produced as in Example 1 and the C-terminal portion of the gene was produced as in Example 2. The DNA sequence for the wild type equine influenza PB2 gene was generated by combining the consensus sequences for the wild type PB2-N protein , denoted nei wt PB2-Nι 2 ι (SEQ ED NO: 13) with the gene fragments for the wild type PB2-C protein, denoted nei wt ιPB2- Cι 233 (SEQ ED NO: 19) and nei wt2 PB2-Cι 232 (SEQ ED NO: 22). The result of combining the consensus sequences from the N-terminal and C-terminal portions of the PB2 wild type influenza virus yielded a complete DNA sequence denoted nei w tPB2 23 ι(SEQ ED NO:44). Translation of SEQ ED NO:44 indicates that the nucleic acid molecule neiwtPB2 2341 encodes a full length equine influenza PB2 protein of about 759 amino acids referred to herein as Pei wt PB2 759 , having amino acid sequence SEQ ED NO: 45, assuming an open reading frame in which the initiation codon spans from nucleotide 28 through nucleotide 30 of SEQ ED NO: 44 and the termination codon spans from nucleotide 2305 through nucleotide 2307 of SEQ ED NO: 44. The region encoding Pei wt PB2 759 , designated nei wt PB2 2277 , and having a coding strand comprising nucleotides 28 to 2304 of SEQ ED NO: 44, is SEQ ED NO: 46. B. A DNA sequence of 2341 nucleotides encoding a cold-adapted equine influenza virus PB2 , denoted nei cal PB2 234 ι, with a sequence denoted SEQ ID NO: 47 was produced by combining the sequences for the N-terminal and C-terminal portions of the PB2 cold-adapted equine influenza gene. The clones for the N-terminal sequences are denoted nei ca ιPB2-Nι 2 ι and nei ca PB2-Nι 24 ι which are identical and are represented by SEQ ED NO: 16. The clones for the C-terminal sequences are denoted nei cal PB2-Cι 23 and nei ca2 PB2-C 123 ι, represented by SEQ ED NO:23. Translation of SEQ ED NO:47 indicates that nucleic acid molecule nei cal PB2 23 ι encodes a full-length equine influenza PB2 protein of about 759 amino acids, referred to herein as Pei cal PB2 59; having amino acid sequence SEQ ED NO:48, assuming an open reading frame in which the initiation codon spans from nucleotide 28 through nucleotide 30 of SEQ ED NO: 47 and the termination codon spans from nucleotide 2305 through nucleotide 2307 of SEQ ED NO:47. The region encoding Pei oal PB2 759 designated nei cal PB2 2277 and having a coding strand comprising nucleotides 28 to 2304 of SEQ ED NO:49. C. Comparison of the nucleic acid sequences of the coding strands of nei wt PB 234 ι (SEQ D NO:44) and nei ca ιPB2 234 ι (SEQ ED NO:47) by DNA alignment reveals the following differences: a T to C base shift at base 370, a A to C base shift at base 1261, and a G to A base shift at base 2037. Comparison of the amino acid sequences of proteins Pei wt PB2 759 (SEQ ID NO:45) and Pei ca ιPB2 759 (SEQ ID NO:48) reveals the following differences: a Y to H shift at amino acid 124 relating to the a T to C shift at base 370 in the DNA sequence, a K to Q shift at amino acid 421 relating to the A to C shift at base 1261 in. the DNA sequence. The third nucleotide shift at base 2037 does not result in an amino acid shift. Example 4 This example describes the cloning and sequencing of equine influenza NS (nonstructural) protein nucleic acid molecules for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus NS proteins were produced as follows. A PCR product containing an equine NS gene was produced by PCR amplification from equine influenza virus DNA and primers w586 and w587, designated SEQ DD NO: 59 and SEQ DD NO: 60, respectively. A nucleic acid molecule of 891 nucleotides encoding a wild-type NS protein, denoted nei wt Sspi, with a coding strand having a nucleic acid sequence designated SEQ ED NO:50 was produced by further PCR amplification using the above-described PCR product as a template and cloned into pCR 2.1 ® TA cloning vector as described in Example 1 A. Plasmid DNA was purified and sequenced as in Example 1 A, except that primers used in the sequencing kits were only T7 and REV. Translation of SEQ ED NO: 50 indicates that nucleic acid molecule neiwuNSsw encodes a full-length equine influenza NS protein of about 230 amino acids, referred to herein as PeiwtιNS 23 o, having amino acid sequence SEQ ED NO:51, assuming an open reading frame in which the initiation codon spans from nucleotide 27 through nucleotide 29 of SEQ ED NO:50 and the termination codon spans from nucleotide 717 through nucleotide 719 of SEQ ED NO: 50. The region encoding PeiwtιNS 230 , designated neiwtιNS69o, and having a coding strand comprising nucleotides 27 to 716 of SEQ ED NO:50 is represented by SEQ ED NO:52. PCR amplification of a second nucleic acid molecule encoding a wild type equine influenza NS protein in the same manner resulted in molecules ne NSsθi, identical to neiwtiNSgpi in the coding region i.e. neiwt 2 NS6 9 o 5 is identical to neiwtι S69o- neiwt 2 NS89i differs from neiwtiNSsgi in one nucleotide at base 827 (G to A) which is 111 bases downstream from the stop codon. PCR amplification of a third nucleic acid encoding a wild type equine influenza NS protein in the same manner resulted in a nucleic acid molecule of 888 nucleotides denoted neiwoNSsss, with a coding strand with a nucleic acid sequence designated SEQ ED NO: 53. ne^ Ssss is identical to neiwtiNSsgi, except that neiwoNS 8 88, lacks two nucleotides on the 5' end and one nucleotide on the 3' end. Translation of SEQ ID NO: 53 indicates that nucleic acid molecule nei^NSsss also encodes Pei w tιNS 30 (SEQ ED NO: 51), assuming an open reading frame having an initiation codon which spans from nucleotide 25 through nucleotide 27 of SEQ ED NO: 53 and a termination codon which spans from nucleotide 715 through nucleotide 717 of SEQ ED NO.53. The nucleic acid molecule having a coding strand comprising nucleotides 25 to 714 of SEQ ID 53, denoted nei w βNSePo, is identical to SEQ ED NO:52. PCR amplification of a fourth nucleic acid of 468 nucleotides encoding a C-terminal portion of the wild type equine influenza NS protein, denoted ne NS^s and having a coding sequence designated SEQ ED NO: 54 was produced. Translation of SEQ ED NO: 54 indicates that nucleic acid molecule nei wt4 NS 4 68 encodes a C-terminal portion of equine influenza NS protein of about 97 amino acids, referred to herein as Peiwt 4 NS 9 , having amino acid sequence SEQ ED NO: 55, assuming an open reading frame having a first codon which spans from nucleotide 3 to 5 of SEQ ED NO: 54, and a termination codon spans from nucleotide 294 through 296 of SEQ ED NO:54. Because SEQ ED NO:54 is only a partial gene sequence, it does not contain an initiation codon. The region encoding Peiwt 4 S9 7 , designated nei w t NS 2 93, and having a coding strand comprising nucleotides 1 to 293 of SEQ ED NO:54, is represented by SEQ ED NO: 56. B. A nucleic acid molecule of 888 nucleotides encoding a cold-adapted equine influenza virus NS protein, denoted neicaiNSsss, with a coding strand having a sequence designated SEQ ID NO: 57 was produced and sequenced as described in part A. Translation of SEQ ID NO:57 indicates that nucleic acid molecule nei cal NS8 88 encodes a full-length equine influenza NS protein of about 230 amino acids, referred to herein as Pei cal NS 23 o, having amino acid sequence SEQ ED NO: 58, assuming an open reading frame in which the initiation codon spans from nucleotide 27 through nucleotide 29 of SEQ ED NO:57 and the termination codon spans from nucleotide 717 through nucleotide 719 of SEQ DD NO:57. The region encoding Pei ca ιNS 23 o, designated nei cal NS 6 9o, and having a coding strand comprising nucleotides 27 to 716 of SEQ ED NO:57, is represented by SEQ ID NO:59. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza NS protein in the same manner resulted in molecules nei ca2 NSg 87 , containing one less nucleotide at the 3' end than nei cal NS888; the coding region nei ca2 NS6 9 o is identical to nei cal NS 6 9o. C. Comparison of the nucleic acid sequences of the coding strands of nei w tNS8 9 i (SEQ DD NO:50) and nei ca ιNS 8 8 8 (SEQ ED NO:57) by DNA alignment reveals the following difference: a A to G shift at base 827 which is 111 bases downstream from the stop codon. The 3' fragment encoding neiwt 4 S 4 68 (SEQ ED NO:54) has one shift T to C found at base 633 relative to the full-length consensus sequence. Comparison of the amino acid sequences of proteins PeiwtNS 230 (SEQ ED NO:51) and Pei ca ιNS 230 (SEQ DD NO:58) reveals that there are no differences between amino acid sequences of the wild type and cold-adapted proteins. Example 5 This example describes the cloning and sequencing of equine influenza PBl protein (RNA-directed RNA polymerase 1) nucleic acid molecules corresponding to the N-terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PB1-N proteins were produced as follows. A PCR product containing a N-terminal portion of the equine PBl gene was produced by PCR amplification from equine influenza virus DNA, and primers T7 and REV. A nucleic acid molecule of 1229 nucleotides encoding a wild type PB1-N protein, denoted nei wt ιPBl-N 1229 , with a coding strand having a nucleic acid sequence designated SEQ ED NO: 62 was produced by further PCR amplification using the above described PCR product as a template and cloned as described in Example IB. Plasmid DNA was purified and sequenced as in Example IB, except that only T7 and REV primers were used in the sequencing kits. Translation of SEQ ED NO: 62 indicates that nucleic acid molecule neiwtiPBl-Nmg encodes a N-terminal portion of influenza PBl protein of about 398 amino acids, referred to herein as PeiwtιPBl-N 3 9 8 , having amino acid sequence SEQ ED NO:63, assuming an open reading frame in which the initiation codon spans from nucleotide 36 through nucleotide 38 of SEQ ED NO:62, and the last codon spans from nucleotide 1227 through nucleotide 1229 of SEQ ED NO:62. The region encoding designated neiwtιPBl-Nn 94 , and having a coding strand comprising nucleotides 36 to 1229 of SEQ ED NO:62 is represented by SEQ ED NO:64. PCR amplification of a second nucleic acid molecule encoding a wild type equine influenza PB1-N protein in the same manner resulted in a nucleic acid molecule of 673 nucleotides denoted with a coding strand with a sequence designated SEQ ED NO.65. Translation of SEQ ED NO:65 indicates that nucleic acid molecule nei w t 2 PB 1- N 673 encodes Peiwt 2 PBl-N 2 ι 2 (SEQ ED NO:66), assuming an open reading frame having an initiation codon which spans from nucleotide 36 through nucleotide 38 of SEQ ED NO:65 and a last codon which spans from nucleotide 671 through nucleotide 673 of SEQ ED NO.65. Because SEQ ED NO:65 is only a partial gene sequence, it does not contain a stop codon. The nucleic acid molecule having a coding strand comprising nucleotides 36 to 671 of SEQ ED NO:65, denoted nei wt2 PBl-N 636 , is designated SEQ ED NO:67. B. A nucleic acid molecule of 1225 nucleotides encoding a N-terminal portion of influenza PBl cold-adapted equine influenza virus PB1-N protein, denoted nei ca ιPBl-Nι 22 s, with a coding strand having a sequence designated SEQ ED NO:68 was produced, and sequenced as described in part A. Translation of SEQ ED NO:68 indicates that nucleic acid molecule nei cal PBl-Nι 225 encodes a N-terminal portion of equine influenza PB-1 protein of about 395 amino acids, referred to herein as Pei ca ιPBl-N 39 5, having amino acid sequence SEQ DD NO:69, assuming an open reading frame in which the initiation codon spans from nucleotide 34 through nucleotide 36 of SEQ ID NO:68, and a last codon which spans from nucleotide 1216 through nucleotide 1218 of SEQ DD NO: 68. The region encoding Pei cal PBl-N 395 , designated nei ca ιPBl-Nπs5, and having a coding strand comprising nucleotides 34 to 1218 of SEQ ED NO:68, is represented by SEQ ID NO:70. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza PB1-N protein in the same manner resulted in molecules nei ca2 PBl-Nι 22 ι, designated SEQ ED NO:71, containing four less nucleotides at the 5' end than nei ca ιPBl- N 1225 ; the coding region nei ca2 PBl-Nn85, is identical to nei ca ιPBl-Nn85. C. Comparison of the nucleic acid sequences of the coding strands of nei wt PBl- N 1229 (SEQ ED NO:62) and nei oal PBl-N 1225 (SEQ ED NO:68) by DNA alignment reveals no differences in the coding regions. Comparison of the amino acid sequences of proteins PeiwtPBl-N 395 (SEQ ED NO:63) and Pei cal PBl-N 395 (SEQ ED NO:69) also reveals no differences. Example 6 This example describes the cloning and sequencing of equine influenza PBl protein (RNA-directed RNA polymerase 1) nucleic acid molecules corresponding to the C-terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PB1-C proteins were produced as follows. A PCR product containing an C-terminal portion of the equine PBl gene was produced by PCR amplification from equine influenza virus DNA, and primer w569 designated SEQ ED NO: 102. A nucleic acid molecule of 1234 nucleotides encoding a wild type PB1-C protein, denoted nei wt ιPBl-Cι 234 , with a coding strand having a nucleic acid sequence designated SEQ ED NO: 85 was produced by further PCR amplification using the above described PCR product as a template and cloned as described in Example IB. Plasmid DNA was purified and sequenced as in Example 1 A, except that different primers were used in the sequencing kits. T7, REV, w569, efPBl-al, designated SEQ DD NO:97, efPBl-a2, designated SEQ ED NO:98, efPBl-sl, designated SEQ ID NO: 99, efPBl-s2, designated SEQ ID NO: 100, and efPBl-s3, designated SEQ DD NO: 101 were used in one instance, T7, REV, efPBl-al, efPBl-a2,efPBl-sl, efPBl-s2, and efPBl-s3 were used in another instance and T7 and REV were used in another instance. Translation of SEQ ID NO: 85 indicates that nucleic acid molecule nei w tιPBl-C 1 34 encodes an C-terminal portion of influenza PBl protein of about 396 amino acids, referred to herein as PeiwtιPBl-C 3 96, having amino acid sequence SEQ ID NO:86, assuming an open reading frame in which the first codon spans from nucleotide 1 through nucleotide 3 of SEQ D NO: 85 and a termination codon which spans from nucleotide 1189 through nucleotide 1191 of SEQ DD NO:85. Because SEQ ID NO:85 is only a partial gene sequence, it does not contain an initiation codon. The region encoding designated neiwtiPBl-Ci , and having a coding strand comprising nucleotides 1 to 1188 of SEQ D NO: 85 is represented by SEQ ID NO: 87. PCR amplification of a second nucleic acid molecule encoding a wild type equine influenza PB1-C protein in the same manner resulted in a nucleic acid molecule of 1240 nucleotides denoted neiwt 2 PBl-Cι 2 o, with a coding strand with a sequence designated SEQ ED NO: 88. Translation of SEQ ED NO: 88 indicates that nucleic acid molecule nei wt2 PBl- Ni 240 encodes a molecule designated Peiwt 2 PBl-C 39 6 (SEQ ED NO: 89) which differs from PeiwtiPBl-Qsge (SEQ ED NO:85) in one nucleotide. i.e. nucleotide 382 of neiwuPBl-Cπss was A, while nucleotide 389 of neiwt 2 PBl-C 1240 , i.e. nucleotide 382 of results in an amino acid change of T to S. B. A nucleic acid molecule of 1241 nucleotides encoding an C-terminal portion of influenza PBl cold-adapted equine influenza virus PB1-C protein, denoted nei cal PBl-Cι ι, with a coding strand having a sequence designated SEQ ED NO:91 was produced, and sequenced as described in part A. Translation of SEQ ED NO:91 indicates that nucleic acid molecule neicaiPBl-Cmi encodes an C-terminal portion of equine influenza PB-1 protein of about 396 amino acids, referred to herein as Pei ca ιPBl-C 9 6, having amino acid sequence SEQ ED NO: 92, assuming an open reading frame in which the first codon spans from nucleotide 8 through nucleotide 10 of SEQ ED NO:91 and a termination codon that spans from nucleotide 1196 through nucleotide 1198 of SEQ D NO:91. Because SEQ ED NO:91 is only a partial gene sequence, it does not contain an initiation codon. The region encoding Pei ca ιPBl-C 396 , designated nei ca ιPBl-Cπ88, and having a coding strand comprising nucleotides 8 to 1195 of SEQ ED NO:91, is represented by SEQ ED NO:93. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza PB1-C protein in the same manner resulted in a nucleic acid molecule of 1241 nucleotides denoted nei ca2 PBl-Cι 2 1 , with a coding strand with a sequence designated SEQ ED NO: 94. Translation of SEQ ED NO: 94 indicates that nucleic acid molecule nei ca2 PBl-Cι 24 ι encodes a molecule designated Pei oa2 PBl-C 3 96 (SEQ ED NO: 95) which differs from Pei ca ιPBl-C 39 6 (SEQ ID NO: 92) in one nucleotide. Nucleotide 1044 of nei ca iPBl-Ci 24 i, i.e. nucleotide 1037 of nei cal PBl-Nn88 was A, while nucleotide 1044 of nei ca2 PBl-Cι 24 ι, i.e. nucleotide 1037 of nei oa2 PBl-Cii 88 was G. Translation of nei ca2 PBl- • Cι 24 ι results in an amino acid change of R to K. C. Comparison of the nucleic acid sequences of the coding strands of nei wt iPBl- Cι 234 (SEQ ID NO:85) and nei ca ιPBl-C 124 ι (SEQ ED NO:91) by DNA alignment reveals the following differences: a C to T shift at base 600 of SEQ D NO:85, and a T to A shift at base 603 of SEQ ED NO: 85. Comparison of the amino acid sequences of proteins Pei w PBl-C 39 6 (SEQ ED NO:86) and Pei oal PBl-N 39 6 (SEQ ED NO:92) reveals the following difference: a H to Q amino acid shift 203 when relating to the T to A base shift at base 603 in the DNA sequences. There is no amino acid shift resulting from the C to T base shift at base 600. Example 7 This example describes the cloning and sequencing of equine influenza PBl protein (RNArdirected RNA polymerase) nucleic acid molecules for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PBl proteins were produced as follows. The wild type or cold-adapted equine influenza genes were cloned in two fragments, the N-terminal portion was produced as in Example 5 and the C-terminal portion of the gene was produced as in Example 6. The DNA sequence for the wild type equine influenza PBl gene was generated by combining the sequences for the wild type PB1-N protein , nei wtl PBl-Nι 22 9 (SEQ ED NO:62) and neiwt 2 PBl-N 673 (SEQ ED NO: 65) with the gene fragments for the wild type PB1-C protein, denoted neiwtιPBl-Cι 234 (SEQ ED NO:85) and neiwt 2 PBl-Cι 240 (SEQ DD NO: 88). The result of combining the N-terminal and C-terminal portions of the PBl wild type influenza virus yielded a complete DNA sequence of 2341 nucleotides denoted neiwtPB 1 2341 (SEQ DD NO: 103). Translation of SEQ ED NO: 103 indicates that the nucleic acid molecule neiwtPB2 2341 encodes a full length equine influenza PBl protein of about 757 amino acids referred to herein as PeiwtPBl 757 , having amino acid sequence SEQ DD NO: 104, assuming an open reading frame in which the initiation codon spans from nucleotide 25 through nucleotide 27of SEQ ID NO: 103 and the termination codon spans , from nucleotide 2293 through nucleotide 2295 of SEQ ED NO: 103. The region encoding, Pei w tPBl 57 designated nei w tPBl 227 ι, and having a coding strand comprising nucleotides 25 to 2292 of SEQ ED NO: 103, is SEQ ED NO: 105. B. A DNA sequence of 2341 nucleotides encoding a cold-adapted equine influenza virus PBl , denoted nei cal PBl 23 ι, with a sequence denoted SEQ ED NO: 106 was produced by combining the sequences for the N-terminal and C-terminal portions of the PBl cold-adapted equine influenza gene. The clones for the N-terminal sequences are denoted nei ca ,PBl-Nι 225 (SEQ DD NO: 68) and nei ca2 PBl-Nι 221 (SEQ ED NO: 71). The clones for the C-terminal sequences are denoted nei ca ιPBl-C 1 1 (SEQ ED NO:91) and nei ca2 PBl-C 1241 ,(SEQ ED NO: 94). Translation of SEQ ED NO: 106 indicates that nucleic acid molecule nei ca ιPBl 3 ι encodes a full-length equine influenza PBl protein of about 757 amino acids, referred to herein as Pei ca ιPBl 757; having amino acid sequence SEQ ED NO: 107, assuming an open reading frame in which the imtiation codon spans from nucleotide 25 through nucleotide 27 SEQ ED NO: 106 and the termination codon spans from nucleotide 2296 through nucleotide 2298 of SEQ ED NO: 106. The.region encoding Pei cal PB 1 757 designated nei ca ιPBl 27 ι and having a coding strand comprising nucleotides 25 to 2295 of SEQ ED NO: 108. C. Comparison of the nucleic acid sequences of the coding strands of nei wt PBl 23 1 (SEQ ED NO:103) and nei cal PBl 234 ι (SEQ ED NO: 106) by DNA alignment reveals the following differences: a C to T base shift at base 1683, and a T to A base shift at base 1686. Comparison of the amino acid sequences of proteins Pei w tPBl 757 (SEQ ED NO: 104) and Pei ca ιPBl 7 5 7 (SEQ ED NO: 107) reveals the following differences: no shift in base C at amino acid 561 relating to the C to T shift at base 1683 , and a H to Q shift at amino acid 562 relating to the a T to A shift at base 1683 in the DNA sequence. Example 8 This example describes the cloning and sequencing of equine influenza PA protein ( RNA polymerase A) nucleic acid molecules corresponding to the C-terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PA-C proteins were produced as follows. A PCR product containing the C-terminal portion of the equine PA gene was produced by PCR amplification using from equine influenza virus DNA and primers C+PA and C-PA, designated SEQ ED NO: 83 and SEQ ED NO: 84 respectively. A nucleic acid molecule of 1228 nucleotides encoding a wild type PA-C protein, denoted nei w tiPA-Cms, with a coding strand having a nucleic acid sequence designated SEQ ED NO: 76 was produced by further PCR amplification using the above- described PCR product as a template and cloned as described in Example IB. Plasmid DNA was purified and sequenced as in Example 1 A, except that different primers were used in the sequencing kits. T7 and REV were used in one instance; P AC- 1, designated SEQ ED NO:72, PAC-2, designated SEQ ED NO:73, PAC-3, designated SEQ ED NO:74, PAC-4, designated SEQ ED NO: 75, T7 and REV were used in another instance; and PAC- 1, PAC-2, T7 and REV were used in another instance. Translation of SEQ ED NO:76 indicates that nucleic acid molecule encodes a C-terminal portion of influenza PA protein of about 388 amino acids, referred to herein as PeiwuPA- ss, having amino acid sequence SEQ ED NO: 77, assuming an open reading frame having a first codon spans from nucleotide 3 through nucleotide 5 of SEQ ED NO:76 and a termination codon which spans from nucleotide 1167 through nucleotide 1169 of SEQ ED NO:76. Because SEQ DD NO:76 is only a partial gene sequence, it does not contain an initiation codon. The region encoding designated nei w uPA- Cιi6 4 , and having a coding strand comprising nucleotides 3 to 1166 of SEQ ED NO: 76 is represented by SEQ DD NO:78. PCR amplification of a second nucleic acid molecule encoding a wild type equine influenza PA-C protein in the same manner resulted in a nucleic acid molecule of 1223 nucleotides denoted with a coding strand with a sequence designated SEQ ED NO:79. neiwt 2 PA-C 1223 is identical to nei w tiPA-Cms, with the exception of a T to C base shift at base 753 and that neiwt 2 PA-Cι 223 lacks five nucleotides on the 3 '-end. Translation of SEQ ED NO:79 indicates that nucleic acid molecule neiwt 2 PA-Cι 23 also encodes PeiwtιPA-C 3 88 (SEQ ED NO:77), assuming an open reading frame having a first codon which spans from nucleotide 3 through nucleotide 5 of SEQ ED NO: 79 and a termination codon which spans from nucleotide 1167 through nucleotide 1169 of SEQ ED NO.79. Because SEQ ED NO:79 is only a partial gene sequence, it does not contain an initiation codon. The nucleic acid molecule having a coding strand comprising nucleotides 3 to 1166 of SEQ ED NO:79, denoted ne PA-Cizs, is identical to SEQ ED NO 78. B. A nucleic acid molecule of 1233 nucleotides encoding a C-terminal portion of influenza PA-C cold-adapted equine influenza virus protein, denoted nei ca ιPA-Cι 23 , and having a coding strand having a sequence designated SEQ ID NO: 80 was produced as described in part A, except that the pCR ® -Blunt cloning vector was used. Translation of SEQ ID NO: 80 indicates that nucleic acid molecule nei ca ιPA-Cι 233 encodes a C-terminal portion of equine influenza PA protein of about 390 amino acids, referred to herein as Pei ca ιPA-C 39 o, having amino acid sequence SEQ DD NO:81, assuming an open reading frame having a first codon which spans from nucleotide 3 through nucleotide 5 of SEQ ED NO: 80 and a termination codon which spans from nucleotide 1173 through nucleotide 1175 of SEQ ED NO:80. Because SEQ ED NO:80 is only a partial gene sequence, it does not contain an initiation codon. The region encoding Pei 0 aiPA-C 39 o, designated nei C aiPA-Cιι 7 o, and having a coding strand comprising nucleotides 3 to 1172 of SEQ ED NO:80, is represented by SEQ ED NO:82. PCR amplification of a second nucleic acid molecule encoding a cold-adapted equine influenza PA-C protein in the same manner resulted in molecule nei ca2 PA-C 1233 , containing one A to G base shift at base 953 as compared to nei ca ιPA-C 1233 ; this base shift does not result in an amino acid change so Pei ca2 PA-C 3 9o, is identical to Pei ca ιPA-C 3 9 0 (SEQ ED NO: 81.) C. Comparison of the nucleic acid sequences of the coding strands of nei w tiPA- Ci 22 8 (SEQ ED NO:76) and nei ca ιPA-C 1233 (SEQ ED NO:80) by DNA alignment reveals the following difference: an C to T base shift at base 753 of SEQ ED NO:80. Comparison of the amino acid sequences of proteins PeiwtιPA-C 3 88 (SEQ ED NO:77) and Pei cal PA- 390 (SEQ ED NO:81) reveals the following difference: a W to R shift at amino acid 251 when relating to the C to T base shift at base 753 in the DNA sequences. Example 9 This example describes the cloning and sequencing of equine influenza PA protein nucleic acid molecules corresponding to the N-terminal portion of the protein, for wild type or cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding wild type or cold-adapted equine influenza virus PA-N proteins were produced as follows. A PCR product containing the N-terminal portion of the equine influenza PA gene was produced using equine influenza virus DNA and primers REV (SEQ ID NO:l), T7 (SEQ DD NO:2), PAN-2 (SEQ ED NO:90), PAN-3 (SEQ D NO:91), PAN-4 (SEQ ED NO:92), and PAN-5 (SEQ ID NO:93). Plasmid DNA was purified and sequenced as in Example 1. A nucleic acid molecule of 1216 nucleotides encoding a wild type PA-N protein, denoted neiwtPA-N 121 6, with a coding strand having a nucleic acid sequence designated SEQ ED NO:X5. Translation of SEQ ED NO:X5 indicates that nucleic acid molecule neiwtPA-Nmδ encodes a N-terminal portion of influenza PA protein of about 397 amino acids, referred to herein as PeiwtPA-N 3 9 7 , having amino acid sequence SEQ ED NO:X7, assuming an open reading frame from the starting methionine (M) through glutamic acid (E) at amino acid 397. The region encoding PeiwtPA-N 397 designated and having a coding strand comprising nucleotides 24 to 1214 of SEQ ED NO:X5, is herein designated SEQ ED NO:X6. B. A nucleic acid molecule of 1217 nucleotides encoding an N-terminal portion of influenza PA-N cold-adapted equine influenza virus protein, denoted nei oa PA-N 1217 , with a coding strand having a nucleic acid sequence designated SEQ ED NO:X8. Translation of SEQ ED NO:X9 indicates that nucleic acid molecule nei ca PA-N 1217 encodes a N-terminal portion of influenza PA protein of about 397 amino acids, referred to herein as Pei ca PA-N 3 9 7 , having amino acid sequence SEQ ED NO:X10, assuming an open reading frame from the starting methionine (M) through glutamic acid (E) at amino acid 397. The region encoding Pei ca PA-N 3 97, designated nei oa PA-N 1193 and having a coding strand comprising nucleotides 25 to 1215 of SEQ ID NO:X8, is designated herein as SEQ ID NO:X9. C. Comparison of the amino acid sequences of proteins Pe^PA-N^ (SEQ ED NO.X7) and Pei ca PA-N 397 (SEQ ED NO:X10) reveals the following differences: a glutamic acid (E) to lysine (K) at amino acid 59 and an alanine (A) to threonine (T) at amino acid 156. Example 10 This example describes the cloning and sequencing of equine influenza PA protein nucleic acid molecules, for wild type or cold-adapted equine influenza viruses. A. The nucleic acid sequences encoding wild type or cold-adapted equine influenza virus PA proteins were compiled as follows. The open reading frame DNA sequence is 2148 nucleotides long for both strains. There is a 214 nucleotide overlap from the C-terminal and N-terminal fragments generated in Examples 8 and 9, respectively. The open reading frame sequences encode the RNA Polymerase A, otherwise known as RNA Polymerase 2 gene, which has 716 amino acid residues from the starting methionine (M) through lysine (K) at amino acid 716. A nucleic acid molecule of 2148 nucleotides encoding the wild type protein is designed neiwtPA 2 ι 48 , and has the coding strand of nucleic acid sequence SEQ ED NO:Xl 1. Translation of SEQ ED NO:Xl 1 indicates that nucleic acid molecule neiwtPA 214 8 encodes the equine influenza virus PA protein of about 716 amino acids, referred to herein as PeivrtPA 716 , having amino acid sequence SEQ ED NO:X12. B. A nucleic acid molecule of 2148 nucleotides encoding the cold-adapted protein is designated nei ca PA 21 8 , and has the coding strand of nucleic acid sequence SEQ ED NO:X13. Translation of SEQ ED NO:X13 indicates that nucleic acid molecule nei ca PA 2148 encodes a protein of about 716 amino acids, referred to herein as PEI ca PA 71 6, having amino acid sequence SEQ ED NO.X14. C. Comparison of the wild type and cold-adapted virus sequences reveals three discrepancies: a G to A base shift at base 175, base 466, and base 870. The base change at base 175 results in a glutamic acid (E) to lysine (K) change at amino acid 59. The base change at 466 results in an alanine (A) to threonine (T) change at amino acid 156. The base change at 870 does not result in an amino acid change at amino acid 290. Example 11 This example describes the cloning and sequencing of equine influenza Neuraminidase (NA) protein nucleic acid molecules for cold-adapted equine influenza viruses. A. Nucleic acid molecules encoding cold-adapted equine influenza virus NA proteins were produced as follows. A PCR product was produced by PCR amplification using equine influenza virus DNA and primers Ml 3 reverse primer (REV) and T7 primer (T7), designated SEQ ID NO:l and SEQ ED NO:2, respectively. A nucleic acid molecule of 1478 molecules encoding the cold-adapted NA protein, denoted nei ca NA 1478 with a coding strand having a nucleic acid sequence designated SEQ ID NO: 87 was produced. Translation of SEQ ED NO: 87 indicates that nucleic acid molecule nei ca NA 1478 encodes a full-length protein of 470 amino acids, referred to herein as Pei ca NA 47 o, having amino acid sequence SEQ ED NO:88, assuming an open reading frame in which the initiation codons spans from nucleotide 29 through 31 of SEQ ED NO: 87 and the termination codon spans from nucleotide 1439 through 1441 of SEQ ED NO:87. The region encoding Pei ca NA 70 , designated nei oa NAι 4 ι 2 , and having a coding strand comprising nucleotide 29 to 1441 of SEQ ED NO:87, is represented by SEQ ED NO:89. Example 12 This example describes the cloning and sequencing of the N-terminal and C- terminal regions of the equine influenza nucleoprotein (NP) nucleic acid molecules for wild type and cold adapted equine influenza virus. A. Nucleic acid molecules encoding wild type and cold adapted equine influenza virus NP proteins were produced as follows. Wild-type strains 1 and 2 were cloned into pCR2.1 (Invitrogen), and cold-adapted strains 1 and 2 were cloned into pCR-Blunt cloning vector (Invitrogen). All strains were sequenced using Ml 3 REV and T7 primers, SEQ ED NO: 1 and SEQ ED NO: 2, respectively. B. N-terminal regions A nucleic acid molecule of 738 nucleotides encoding the N-terminus of the wild- type strain 1 NP protein, denoted nei w u NP-N 7 8 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 104, was produced. Translation of SEQ ED NO: 104 indicates that nucleic acid molecule neiwti NP-N 73 s encodes the N-terminal 246 amino acids of NP protein, designated Pei w NP-N 246 , having amino acid sequence SEQ ID NO: 105. A nucleic acid molecule of 693 nucleotides encoding the N-terminus of the wild- type strain 1 NP protein, denoted nei wtl NP-N 693 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 106 was produced. Translation of SEQ ID NO: 106 indicates that nucleic acid molecule nei wtl NP-N 693 encodes the N-terminal 231 amino acids of NP protein, designated Peiw NP-N 23]1 , having amino acid sequence SEQ ID NO: 107. A nucleic acid molecule of 738 nucleotides encoding the N-terminus of the wild- type strain 2 NP protein, denoted nei wt2 NP-N 738 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 108, was produced. Translation of SEQ ID NO: 108 indicates that nucleic acid molecule nei wt2 NP-N 738 encodes the N-terminal 246 amino acids of NP protein, designated Pei wt2 NP-N 246 , having amino acid sequence SEQ ID NO: 109. A nucleic acid molecule of 693 nucleotides encoding the N-terminus of the wild- type strain 2 NP protein, denoted nei wt2 NP-N 693 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 110, was produced. Translation of SEQ ID NO: 110 indicates that nucleic acid molecule nei wt2 NP-N 693 encodes the N-terminal 231 amino acids of NP protein, designated Pei wt2 NP-N 231 , having amino acid sequence SEQ ID NO:lll. An N-terminal protein fragment of 245 amino acids of NP protein, designated Pei cal NP-N 245 , having amino acid sequence SEQ ID NO: 112, was generated. A nucleic acid molecule of 690 nucleotides encoding the N-terminus of the cold- adapted strain 1 NP protein, denoted nei cal NP-N 690 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 113, was produced. Translation of SEQ ID NO: 113 indicates that nucleic acid molecule nei cal NP-N 690 encodes the N-terminal 230 amino acids of NP protein, designated Pei cal NP-N 230 , having amino acid sequence SEQ ID NO: 114. A nucleic acid molecule of 735 nucleotides encoding the N-terminus of the cold- adapted strain 2 Np protein, denoted nei ca2 NP-N 735 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 115 was produced. Translation of SEQ ID NO: 115 indicates that nucleic acid molecule nei ca2 NP-N 735 encodes the N-terminal 245 amino acids of NP protein, designated Pei ca2 NP-N 245 , having amino acid sequence SEQ ID NO:116. A nucleic acid molecule of 690 nucleotides encoding the N-terminus of the cold- εdapted strain 2, denoted nei ca2 NP-N 690 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 117, was produced. Translation of SEQ ID NO: 117 indicates that nucleic acid molecule nei ca2 NP-N 690 encodes the N-terminal 230 amino acids of NP protein, designated Pei ca2 NP-N 230 , having amino acid sequence SEQ ID NO: 118. C. C-terminal regions A nucleic acid molecule of 679 nucleotides encoding the C-terminal of the wild type strain 1, denoted nei wtl NP-C 679 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 119, was produced. Translation of SEQ ID NO: 119 indicates that nucleic acid molecule nei wtl NP-C 679 encodes the C-terminal 226 amino acids of NP protein, designated Pei wtl NP-C 226 , having amino acid sequence SEQ ID NO: 120. A nucleic acid molecule of 656 nucleotides encoding the C-terminal of the wild type strain 1, denoted nei wtl NP-C 656 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 121, was produced. Translation of SEQ ID NO: 121 indicates that nucleic acid molecule nei wtl NP-C 656 encodes the C-terminal 218 amino acids of NP protein, designated Pei wα NP-C 218 , having amino acid sequence SEQ ID NO: 122. A nucleic acid molecule of 679 nucleotides encoding the C-terminal of the wild type strain 1, denoted nei wt2 NP-C 679 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 123, was produced. Translation of SEQ ID NO: 123 indicates that nucleic acid molecule nei wt2 NP-C 679 encodes the C-terminal 226 amino acids of NP protein, designated Pei wt2 NP-C 226 , having amino acid sequence SEQ ID NO: 124. A nucleic acid molecule of 656 nucleotides encoding the C-terminal of the wild type strain 2, denoted nei wt2 NP-C 656 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 125, was produced. Translation of SEQ ID NO: 125 indicates that nucleic acid molecule nei wt2 NP-C 656 encodes the C-terminal 218 amino acids of NP protein, designated Pei wt2 NP-C 218 , having amino acid sequence SEQ ID NO: 126. A nucleic acid molecule of 656 nucleotides encoding the C-terminal of the cold- adapted strain 1, denoted nei ca ι NP-C 665 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 127, was produced. Translation of SEQ ID NO: 127 indicates that nucleic acid molecule nei ca] NP-C 665 encodes the C-terminal 222 amino acids of NP protein, designated Pei cal NP-C 222 , having amino acid sequence SEQ ID NO: 128. A nucleic acid molecule of 642 nucleotides encoding the C-terminal of the cold- adapted strain 1, denoted nei ca ι NP-C 642 , with a coding strand having a nucleic acid sequence designated SEQ ID NO: 129 was produced. Translation of SEQ ID NO: 129 indicates that nucleic acid molecule nei cal NP-C 642 encodes the C-terminal 214 amino acids of NP protein, designated Pei cal NP-C 2!4 , having amino acid sequence SEQ ID NO:130. D. Comparisons Consensus sequences for the 5' and 3' ends of the NP gene were generated, but there is an approximately 148 base pair gap in the data that prevents the formation of a contiguous sequence when compared to protein and DNA data currently in the GenBank databases (a nucleoprotein from GenBank named flanpg; Gorman et al, J. Virol. 64, 1487 (1990)). The flanpg sequences were used to compare the 5' and 3' fragments of the present NP genes to get relative positions that are used to designate position for the various differences in the bases between the Wild Type and the ca strains. The flanpg sequence allows for the approximately 148 base pairs that are missing between the 5' and 3' fragments needed to construct the entire gene. The DNA codes for the N-terminal 735-738 bases and the C-terminal 665-679 bases with a gap of approximately 149-166 bases between the two fragments of the Wild Type and cold-adapted (ca) strains, respectively. There are seven discrepancies between the wild type and ca strains. The ca strains have discrepancies at base 146 (G to T) and at base 228 (A to G). At base 492, the wtl only has a discrepancy versus the other strains of (A to C). At base 541, the cal only has a discrepancy versus the other strains of (C to A). There is a base discrepancy at position 645 in the DNA (G to A). At base 670, the ca strains have a discrepancy (G to A). At base 1019, the wtl only has a discrepancy versus the other strains of (G to A). There are no other points of discrepancy between the full-length Wild Type and ca strains. The full-length sequence is proposed to consist of 1497 bases, however there is no overlap between the 5' and 3' ends of the DNA sequences generated. The sequences listed are for the 5' end and the 3' end of the open reading frame of the gene. The gene is missing approximately 148 base pairs between these two fragment sequences that would generate the complete gene sequence. A comparison of all the Wild Type and ca strain clones (wtl, wt2, cal, and ca2) by amino acid translation for the protein sequence coding only for the open reading frame (ORF) from the 5' and 3' DNA fragments was compared to the GenBank nucleoprotein noted above. The DNA codes for the N-terminal 230 amino acids and the C-terminal 214 amino acids with a gap of approximately 55 amino acids between the two fragments. There are seven discrepancies between the ca and Wild Type strains. The ca strains have a discrepancy (G to V) at amino acid 34, and at amino acid 61 (I to M). At amino acid 149, the wtl only has a discrepancy versus the other strains of (Q to H). At amino acid 166, cal only has a discrepancy versus the other strains of (L to M). Although there is a base discrepancy at position 600 in the DNA sequence, there is no change in the corresponding amino acid sequence. At amino acid 209, the ca strains have a discrepancy (G to S). At amino acid 325, the wtl only has a discrepancy versus the other strains of R to K). There are no other points of discrepancy between the full-length Wild Type and ca strains. While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

Claims: What is claimed: 1. An isolated equine influenza nucleic acid molecule selected from the group consisting of: a. an isolated nucleic acid molecule that encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ED NO: 6, SEQ ED NO:9, SEQ ED NO: 14, SEQ ED NO:22, SEQ ED NO:25, SEQ ED NO:28, SEQ ED NO:33, SEQ ED NO:37, SEQ ED NO:40, SEQ ED NO:43, SEQ ED NO:46, SEQ ED NO:49, SEQ ED NO:54, SEQ DD NO:62, SEQ ID NO:64, SEQ ED NO:67, SEQ ED NO:69, SEQ ED NO:72, SEQ ED NO:77, SEQ ED NO:85, SEQ ED NO:88, SEQ ED NO:96, SEQ ED NO:99, SEQ ED NO: 101, SEQ E O:103, SEQ DD NO: 105, SEQ ID NO: 107, SEQ ED NO: 109, SEQ ED NO: 111, SEQ ED NO: 112, SEQ ED NO: 114, SEQ DD NO: 116, SEQ DD NO:l 18, SEQ ED NO: 120, SEQ ED NO: 122, SEQ ED NO: 124, SEQ ED NO: 126, SEQ ED NO: 128, and SEQ DD NO: 130; and b. an isolated nucleic acid molecule fully complementary to a nucleic acid molecule of (a). 2. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ED O:7, SEQ ID O:8, SEQ ED NO:10, SEQ ED NO:13, SEQ ID NO: 19, SEQ ED NO:20, SEQ ED NO:21, SEQ ED NO:23, SEQ ED NO:24, SEQ ED NO:26, SEQ ED NO:27, SEQ DD NO:29, SEQ ID NO:32, SEQ ED NO:34, SEQ ED NO:35, SEQ ED NO:36, SEQ DD NO:38, SEQ ED NO:39, SEQ ED NO:41, SEQ ED NO:42, SEQ ED NO:44, SEQ ED NO:45, SEQ ED NO:47, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:51, SEQ ED NO:53, SEQ ED NO:60, SEQ ED NO:61, SEQ ED NO:63, SEQ ED NO:65, SEQ ED NO:66, SEQ ED NO:68, SEQ ED NO:70, SEQ ED NO:71, SEQ ED NO:73, SEQ ED NO:76, SEQ ED NO:82, SEQ DD NO:83, SEQ ED NO:84, SEQ ED NO:86, SEQ DD NO:87, SEQ ED NO:89, SEQ ED NO:94, SEQ ED NO:95, SEQ ED NO:97, SEQ ED NO:98, SEQ ED NO:100, SEQ ED NO:102, SEQ DD NO:104, SEQ DD NO:106, SEQ DD NO:108, SEQ ED NO:110, SEQ ED O:113, SEQ ED NO.115, SEQ ED NO:117, SEQ ED NO:119, SEQ ED NO:121, SEQ ED NO:123, SEQ ED O:125, SEQ ED NO: 127, and SEQ ED NO: 129 and a nucleic acid molecule comprising a nucleic acid sequence which is fully complementary to any of said nucleic acid sequences. 3. A nucleic acid molecule of Claim 1, wherein said nucleic acid molecule encodes a protein. 4. A nucleic acid molecule of Claim 1, wherein said nucleic acid molecule is selected from the group consisting of nei ca ιNS69o, nei oa ιNS8 8 8, nei cal PA-Cιι 7 o,nei C aiPA-C 1233 , nei oal PBl-C U 88, nei cal PBl-Cι 24 ι, nei ca ιPBl-N π85 , nei ca ιPBl-Nι 225 , nei cal PBl 2271 , nei cal PBl 2341 , nei cal PB2 2277 , nei cal PB2 234 ι, nei ca2 PBl-Cι 24 ι, nei oa2 PBl-Nπ8 5 , nei ca2 PBl-Nι 22 ι, nei ca NA 147 8,nei ca NA 470 , nei 0 aPA-Nn 93 , nei ca PA-N 12 ι 7 , nei ca PA 2 ι 48 , neiwtιNS 6 9o, neiwuNSsgi, neiwtιPA-Cπ6 , neiwtιPA-Cι 228 , neiwtiPBl-Cnss, neiwtιPBl-Nι 229 , neiwtιPBlNπ 94 , neiwt2PA-C 1223 , neiwt 2 PBl-Cι 240 , nei^PBl-Nese, neiwt 2 PBl-N67 3 , ne STSsss, neiwt 4 NS 2 9 3 , neiwt 4 NS 46 8, neiwtPA-N 1193 , newPA-Nme, nei wt PA 2 ι 48 , neiwtPBl 227 ι, neiwtPBl 2341 , nei wt PB2 2277 , neiwtPB2 2341 , nei wt PB2-Nι 24 ι, neiwtPB2-N 1214 , nei ca ιPB2-Cι 232 , nei oa ιPB2-Cπ94, nei ca ιPB2-Nι 214 , neiwtPB2-Cι 233 , neiwtPB2-Cii 94 , neiwt PB2-Cι 232 , neiwtNS 8 9i, neiwtNSego, neiwtιNP-N 738 , neiwtiNP-Negs, nei^NP-N^s, ne P-Negs, nei ca iNP-N 6 9o, nei ca2 NP-N 73 5, nei ca2 NP-N 6 9 0 , nei wt ιNP-C 67 9, neiwuNP-Cese, neiwt 2 NP-C 67 9, neiwt 2 NP-C 6 56, nei ca ιNP-C 6 65, nei cal NP-C 6 2 . 5. An isolated equine influenza protein that comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ED NO:9, SEQ ID NO: 14, SEQ ED NO:22, SEQ ED NO:25, SEQ ED NO:28, SEQ ED NO:33, SEQ ED NO:37, SEQ ED NO:40, SEQ ED NO:43, SEQ DD NO:46, SEQ DD NO:49, SEQ ID NO:54, SEQ ID NO:62, SEQ ED NO:64, SEQ DD NO:67, SEQ ED NO:69, SEQ ED NO.72, SEQ ED NO:77, SEQ ED NO.85, SEQ ED NO:88, SEQ ED NO:96, SEQ ID NO:99, SEQ DD NO: 101, SEQ DD NO: 103, SEQ DD NO: 105, SEQ ED NO: 107, SEQ ID NO: 109, SEQ DD NO:l l l, SEQ DD O:112, SEQ ED NO:114, SEQ ED O:116, SEQ ED NO:118, SEQ ED NO: 120, SEQ ED NO: 122, SEQ ED NO: 124, SEQ ED NO: 126, SEQ ED NO: 128, and SEQ ED NO: 130. 6. The protein of Claim 5, wherein said protein is encoded by a nucleic acid molecule selected from the group consisting of SEQ ED NO.5, SEQ ED NO:7, SEQ ED NO.8, SEQ ED NO:10, SEQ ED NO:13, SEQ ED NO:19, SEQ ED NO:20, SEQ ED NO:21, SEQ ED NO:23, SEQ ED NO:24, SEQ DD NO:26, SEQ ED NO:27, SEQ ED NO:29, SEQ ED NO:32, SEQ ED NO:34, SEQ ED NO.35, SEQ ED NO:36, SEQ ED NO:38, SEQ ED NO:39, SEQ ED NO:41, SEQ ED NO:42, SEQ ED NO:44, SEQ DD NO:45, SEQ DD NO:47, SEQ ED NO:48, SEQ ED NO:50, SEQ ED NO:51, SEQ ED NO:53, SEQ ED NO:60, SEQ ED NO:61, SEQ ED NO:63, SEQ ED NO:65, SEQ ED NO:66, SEQ ED NO:68, SEQ ED NO:70, SEQ ED NO:71, SEQ ED NO:73, SEQ ED NO:76, SEQ ED NO:82, SEQ ED NO:83, SEQ ED NO:84, SEQ DD NO:86, SEQ DD NO:87, SEQ ED NO:89, SEQ ED NO:94, SEQ ED NO:95, SEQ ED NO:97, SEQ DD NO:98, SEQ ED NO-.100, SEQDDNO:102, SEQEDNO:104, SEQEDNO:106, SEQEDNO:108, SEQ ED NO:110, SEQEDNO:113, SEQEDNO:115, SEQEDNO:117, SEQEDNO:119, SEQ ID NO:121, SEQDDNO:123, SEQEDNO:125, SEQEDNO.127, and SEQEDNO:129. 7. An isolated virus comprising a nucleic acid molecule that encodes a protein selected from the group consisting SEQ ID NO:6, SEQ ED NO:9, SEQ ED NO: 14, SEQ ED NO:22, SEQ ED NO:25, SEQ ED NO:28, SEQ ED NO:33, SEQ ED NO:37, SEQ ED NO:40, SEQ DD NO:43, SEQ D NO:46, SEQ ED NO:49, SEQ ID NO:54, SEQ ED NO:62, SEQ D NO:64, SEQ ED NO:67, SEQ ED NO:69, SEQ ED NO:72, SEQ ED NO:77, SEQ ED NO:85, SEQ ED NO:88, SEQ ID NO:96, SEQ ED NO:99, SEQ ED NO.iOl, SEQ ED NO: 103, SEQ DD NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO-.lll, SEQ DNO:112, SEQIDNO:114, SEQIDNO:116, SEQEDNO:118, SEQ ED NO: 120, SEQ ED NO: 122, SEQ ED NO: 124, SEQ DD NO: 126, SEQ ED NO: 128, and SEQ EDNO:130. 8. The virus of Claim 7, wherein said virus comprises a nucleic acid sequence selected from the group consisting of SEQ ED NO:5, SEQ ED NO:7, SEQ ED NO:8, SEQ ID NO: 10, SEQ DD NO: 13, SEQ DD NO: 19, SEQ ID NO:20, SEQ ED NO:21, SEQ DD NO:23, SEQ ED NO:24, SEQ ED NO:26, SEQ ED NO:27, SEQ ED NO:29, SEQ ED NO:32, SEQ ED NO:34, SEQ D NO:35, SEQ DD NO:36, SEQ DD NO:38, SEQ DD NO:39, SEQ ED NO:41, SEQ ED NO:42, SEQ ED NO:44, SEQ ID NO:45, SEQ ED NO:47, SEQ DD NO:48, SEQ DD NO:50, SEQ DD NO:51, SEQ ED NO:53, SEQ ED NO:60, SEQ ED NO:61, SEQ ED NO:63, SEQ ED NO:65, SEQ ED NO:66, SEQ ED NO:68, SEQ D NO:70, SEQ DD NO:71, SEQ ED NO:73, SEQ ED NO:76, SEQ ED NO:82, SEQ DD NO:83, SEQ DD NO:84, SEQ DD NO:86, SEQ ED NO:87, SEQ ED NO:89, SEQ ED NO:94, SEQ ED NO:95, SEQ ED NO:97, SEQ ED NO:98, SEQ ED NO:100, SEQED O:102, SEQEDNO:104, SEQEDNO:106, SEQEDNO:108, SEQ ED NO:110, SEQEDNO:113, SEQEDNO:115, SEQE NO:117, SEQEDNO:119, SEQED NO.121, SEQ ED NO: 123, SEQ ED NO: 125, SEQ ED NO: 127, and SEQ ED NO: 129. 9. The virus of Claim 7, wherein said virus is selected from the group consisting of equine influenza virus and a reassortant influenza virus.

Inventors: DOWLING PATRICIA W, YOUNGNER JULIUS S, DOWLING, PATRICIA, W., YOUNGNER, JULIUS, S.
Applicants: DOWLING PATRICIA W, UNIV PITTSBURGH, YOUNGNER JULIUS S, DOWLING, PATRICIA, W., THE UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, YOUNGNER, JULIUS, S.
Application year: 2001
Main classification: C07K14
IPC codes: C07K14, C12N7